New hope for rare fat disorder: safety trial launches

NCT ID NCT05185843

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This study tests a new drug called olezarsen in 24 adults with familial chylomicronemia syndrome (FCS), a rare condition causing extremely high blood fats. Participants have previously taken volanesorsen. The main goal is to check safety, especially effects on blood cells and organs, while also measuring how well the drug lowers triglycerides. This is an open-label study, meaning everyone knows they are getting the active drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ARC Biosystems, Clinical Assessment Unit (CAU)

    Vancouver, British Columbia, V6Z 2C7, Canada

  • Centre Hospitalier Universite de Sherbrooke (CHUS)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Centre for Heart Lung Innovation

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • Clinique des Maladies Lipidiques de Quebec Inc.

    Québec, Quebec, G1V 4W2, Canada

  • Diabetes/Lipid Management & Research Center

    Huntington Beach, California, 92648, United States

  • Ecogene-21

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Excel Medical Clinical Trials, LLC

    Boca Raton, Florida, 33434, United States

  • Karolinska University Hospital Huddinge

    Stockholm, 171 77, Sweden

  • St. Boniface General Hospital

    Winnipeg, Manitoba, R2H 2Ab, Canada

  • University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND)

    Ann Arbor, Michigan, 48109-2800, United States

  • University of Rochester School of Medicine

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.